Substance abuse treatment, prevention, and policy
-
Subst Abuse Treat Prev Policy · Jan 2015
Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio.
Buprenorphine is under-utilized in treating opioid addiction. Payers and providers both have substantial influence over the adoption and use of this medication to enhance recovery. Their views could provide insights into the barriers and facilitators in buprenorphine adoption. ⋯ This qualitative analysis found that attitudes toward use of medication and medication funding environment play important roles in an organization's decision to begin buprenorphine use and that physician availability influences an organization's ability to expand buprenorphine use over time. Additional education, reimbursement support, and policy changes are needed to support buprenorphine adoption and use, along with a greater understanding of the roles payers, providers, and regulators play in the adoption of targeted practices.
-
Subst Abuse Treat Prev Policy · Jan 2015
Views about responsibility for alcohol addiction and negative evaluations of naltrexone.
Moral philosophers have debated the extent to which persons are individually responsible for the onset of and recovery from addiction. Empirical investigators have begun to explore counselors' attitudes on these questions. Meanwhile, a separate literature has investigated counselors' negative attitudes towards naltrexone, an important element of medication-assisted treatment for alcohol addiction. The present study bridges the literature on counselor views about responsibility for addiction with the literature on attitudes towards naltrexone. It investigates the extent to which a counselor's views of individual responsibility for alcohol addiction are related to that counselor's views of naltrexone. ⋯ We conclude that there is a strong relationship between a counselor assigning higher individual responsibility for addiction and holding more negative views about naltrexone. The study also sheds light on one reason why the model of addiction as a brain disease has had limited impact on clinical practice.